DRMA
Dermata Therapeutics, Inc. (DRMA) 10Y Growth Potential Analysis (2026)
No material changes this month.
Revenue Growth Drivers
Reported five-year revenue CAGR is unavailable, so long-term growth evidence is limited versus peers with disclosed multi-year compounding histories.
Negative TTM ROIC suggests current capital deployment is not yet generating scalable incremental revenue, weakening reinvestment-led growth versus stronger peers.
Low net debt to EBITDA indicates balance-sheet capacity exists for expansion, but it has not yet translated into proven revenue compounding.
Near-zero capex intensity implies limited asset-heavy scaling needs, which can support growth flexibility, though peer advantage remains unproven.
Market Tailwinds
No segment concentration or market-share data is provided, so durable demand visibility cannot be established against peers with clearer end-market exposure.
Absence of disclosed revenue CAGR prevents confirmation that the company is benefiting from a stronger structural demand tailwind than competitors.
Negative free cash flow yield implies current economics are not yet supporting self-funded expansion, limiting evidence of compounding tailwinds.
Without peer-comparable operating disclosures, the company appears closer to a mature or early-stage profile than a structurally advantaged compounder.
Scalability Expansion
Very low capex-to-revenue suggests the model may scale without heavy asset buildup, but peer-relative proof of efficient expansion is missing.
Low leverage provides some financing flexibility for growth initiatives, although current returns do not show that capital is being converted into scale.
Negative ROIC indicates expansion has not yet produced attractive incremental economics, which caps confidence in durable multi-year scaling.
No R&D intensity or segment data is available, limiting evidence that the company can broaden products or markets faster than peers.
Constraints Limitations
Negative ROIC is the clearest structural constraint, because it signals reinvestment is not currently compounding revenue or value versus peers.
Negative free cash flow yield limits internally funded expansion, reducing the company’s ability to scale faster than better-capitalized peers.
Missing five-year growth and segment data materially weakens visibility into durable expansion, making long-term scaling harder to underwrite.
The available metrics show financial flexibility, but they do not yet demonstrate a repeatable growth engine with peer-leading durability.
Overall Score
DRMA shows some balance-sheet and asset-light scaling flexibility, but negative ROIC and weak cash generation limit evidence of durable long-term revenue compounding versus peers.
Score Driver: Negative ROIC
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Dermata Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
